LY-334,370
From Wikipedia, the free encyclopedia
(Redirected from LY334370)
| LY-334,370 | |
|---|---|
 |
|
|
4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide |
|
|
Other names
LY-334,370 |
|
| Identifiers | |
| CAS number | 182563-08-2 |
| PubChem | 5311258 |
| IUPHAR ligand | 20 |
| Jmol-3D images | Image 1 |
|
|
| Properties | |
| Molecular formula | C21H22FN3O |
| Molar mass | 351.42 g/mol |
 (verify) (what is:  / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
LY-334,370 is a selective 5-HT1F receptor agonist[1] which was under development by Eli Lilly and Company for the treatment of migraine headaches.[2] The drug showed efficacy in a phase II clinical trial[3] but further development was halted due to toxicity detected in animals.[4]
[edit] See also
- Lasmiditan, another 5-HT1F agonist for the treatment of migraine
[edit] References
- ^ Dupuis DS, Colpaert FC, Pauwels PJ (1998). "G-protein activation at 5-HT1A receptors by the 5-HT1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines". Br. J. Pharmacol. 124 (2): 283–90. doi:10.1038/sj.bjp.0701832. PMID 9641544.
- ^ Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R (1999). "Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY-334,370". Cephalalgia 19 (10): 851–8. doi:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103.
- ^ Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001). "Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial". Lancet 358 (9289): 1230–4. doi:10.1016/S0140-6736(01)06347-4. PMID 11675061.
- ^ Ramadan NM, Buchanan TM (2006). "New and future migraine therapy". Pharmacol. Ther. 112 (1): 199–212. doi:10.1016/j.pharmthera.2005.04.010. PMID 16797716.
[edit] External links
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
